Table 2.
Observed cases of HIV-related cryptococcal antigenemia in pregnancy in Uganda from 2012 to 2018.
| No. | Disease severity | Treatment* | Duration of symptoms (days) | EGA (weeks) | Age | Recent CD4+ count (cells/μL) | ART status | Outcome of mother | Outcome of baby |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Asymptomatic | Fluconazole: 200 mg/day postpartum | N/A | Exclusively breastfeeding (8 months postpartum) | 25 | N/A | ART experienced (TDF/3TC/EFV), unknown duration | Alive at six months | Alive, CrAg- at 6 months |
| 2 | Asymptomatic (Serum CrAg titers 1:20) | Amphotericin B: 10 doses throughout pregnancy | N/A | 24 | 34 | N/A | ART experienced (TDF/3TC/EFV), unknown duration | Alive postpartum | Alive |
| 3 | Asymptomatic | Unknown | N/A | Unknown | 27 | 73 | ART experienced (TDF/3TC/NVP), 1 year | Alive at six months | Unknown |
| 4 | Asymptomatic (Serum CrAg titers 1:5000) | Unknown | N/A | Unknown | 35 | 69 | ART naive | Alive at six months | Unknown |
| 5 | Symptomatic (Fingerstick CrAg+, CSF CrAg-) | Unknown | 10 | Unknown | 21 | 38 | ART experienced, unknown regimen and duration | Alive at hospital discharge | Unknown |
| 6 | Symptomatic, CSF India ink + (History of CM) | Fluconazole: Was receiving 400 mg/day prior to CrAg screening | 14 | Unknown | 29 | 160 | ART experienced (AZT/3TC/EFV), 2 years | Alive at hospital discharge | Unknown |
Abbreviations: CM, cryptococcal meningitis; EGA, estimated gestational age; N/A, not available. *Amphotericin B = amphotericin B deoxycholate (0.7–1.0 mg/kg).